Chris Henry

Chris Henry has extensive work experience in the field of process chemistry and CMC (Chemistry, Manufacturing, and Controls). Chris currently holds the position of Senior Director of CMC at CoA Therapeutics, Cantero Therapeutics, and Navire Pharma, all subsidiaries of BridgeBio. Chris has been in this role since March 2020 and is still actively involved in these companies.

Before joining BridgeBio, Chris worked at Protagonist Therapeutics as an Associate Director of Process Chemistry from October 2018 to February 2020.

Prior to that, they worked at Achaogen, where they had several roles including Associate Director of Process Chemistry, Senior Scientist, Scientist II, and Scientist I. Their tenure at Achaogen lasted from August 2011 to October 2018.

Chris also has research experience as a Postdoctoral Scholar at Caltech from October 2008 to June 2011.

Chris Henry completed their education in Synthetic Organic Chemistry at UCLA, where they pursued a PhD from 2003 to 2008. Prior to this, they obtained a Bachelor of Science degree in Chemistry & Biology from William & Mary, where they studied from 1999 to 2003.